NATICK , Mass . , July 16 / PRNewswire-FirstCall / -- Boston Scientific Corporation ( NYSE : BSX ) today announced it has received approval from the U.S. Food and Drug Administration ( FDA ) to market its TAXUS ( ( R ) ) Liberte ( ( R ) ) Long Paclitaxel-Eluting Coronary Stent System , a next-generation drug-eluting stent ( DES ) designed for long lesions . At 38 mm , it is the longest available DES , providing doctors an option that can potentially reduce the number of stents used in more complex cases , simplifying procedures and reducing costs . It affords a more efficient treatment option for the estimated 8 to 10 percent ( 1 ) of patients with long lesions . The Company plans to launch the product in the U.S. next month . It received CE Mark approval in 2007 .